Congenital cutaneous candidiasis associated with respiratory distress in a full-term newborn.
BACKGROUND
Congenital candidiasis is rare occurring in most cases in premature and low birth weight new born. It can produce a spectrum of disease ranging from a diffuse skin eruption to a severe systemic disease with or without skin involvement. Amphotericin B is the first-line agent for the treatment of systemic disease.


OBJECTIVE
To describe a congenital candidiasis in a full-term newborn.


METHODS
At birth, the newborn had a generalized, erythematous, papulovesicular eruption. He was treated by topic antifungal therapy. However, on the third day, he developed a systemic disease with respiratory distress and fever. Ear, skin swab and gastric aspirate grew to Candida albicans. The newborn was given fluconazole for 10 days with favourable outcome.


CONCLUSIONS
Early topic therapy did not prevent systemic spread of congenital cutaneous candidiasis in our case. Treatment with fluconazole, as the first-line agent, seems effective and safe.
Department of Pediatrics B, Children's Hospital of Tunis, Tunis, Tunisia.
Faten
F
Tinsa
Khadija
K
Boussetta
Dalel
D
Ben Hassine
Monia
M
Kharfi
Souad
S
Bousnina
D000935:Antifungal Agents / Q000627:therapeutic use; D002179:Candidiasis, Cutaneous / Q000150:complications* / Q000151:congenital* / Q000188:drug therapy; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy / Q000209:etiology*
D000935:Antifungal Agents; D015725:Fluconazole